BR112023025904A2 - Molécula de ligação biespecífica - Google Patents

Molécula de ligação biespecífica

Info

Publication number
BR112023025904A2
BR112023025904A2 BR112023025904A BR112023025904A BR112023025904A2 BR 112023025904 A2 BR112023025904 A2 BR 112023025904A2 BR 112023025904 A BR112023025904 A BR 112023025904A BR 112023025904 A BR112023025904 A BR 112023025904A BR 112023025904 A2 BR112023025904 A2 BR 112023025904A2
Authority
BR
Brazil
Prior art keywords
binding molecule
bispecific binding
biespecific
single chain
identical antibody
Prior art date
Application number
BR112023025904A
Other languages
English (en)
Inventor
Ken Honek
Lisa Sandersjoo
Per-Ola Freskgard
Ronny Falk
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of BR112023025904A2 publication Critical patent/BR112023025904A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

molécula de ligação biespecífica. é fornecida uma molécula de ligação biespecífica, que compreende duas cadeias pesadas de anticorpo idênticas e um componente de cadeia única que é uma cadeia polipeptídica compreendendo duas cadeias leves de anticorpo idênticas ligadas a um módulo de ligação de cadeia única com afinidade por um alvo que medeia o transporte da molécula de ligação biespecífica ao longo da barreira hematoencefálica (bbb). também são fornecidos usos terapêuticos, profiláticos, prognósticos e diagnósticos da molécula de ligação biespecífica.
BR112023025904A 2021-06-11 2022-06-10 Molécula de ligação biespecífica BR112023025904A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21179103 2021-06-11
PCT/EP2022/065915 WO2022258841A1 (en) 2021-06-11 2022-06-10 Bispecific binding molecule

Publications (1)

Publication Number Publication Date
BR112023025904A2 true BR112023025904A2 (pt) 2024-02-27

Family

ID=76444245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025904A BR112023025904A2 (pt) 2021-06-11 2022-06-10 Molécula de ligação biespecífica

Country Status (9)

Country Link
US (1) US20240141027A1 (pt)
EP (1) EP4351726A1 (pt)
KR (1) KR20240019125A (pt)
CN (1) CN117693531A (pt)
AU (1) AU2022291255A1 (pt)
BR (1) BR112023025904A2 (pt)
CA (1) CA3220572A1 (pt)
IL (1) IL308394A (pt)
WO (1) WO2022258841A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114499A1 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
KR101413615B1 (ko) 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
KR102099462B1 (ko) 2010-11-30 2020-04-10 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
RS58928B1 (sr) 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
BR112019000098A2 (pt) 2016-07-14 2019-04-09 Bioarctic Ab proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio

Also Published As

Publication number Publication date
CN117693531A (zh) 2024-03-12
WO2022258841A1 (en) 2022-12-15
US20240141027A1 (en) 2024-05-02
KR20240019125A (ko) 2024-02-14
CA3220572A1 (en) 2022-12-15
AU2022291255A1 (en) 2024-01-04
EP4351726A1 (en) 2024-04-17
IL308394A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
PE20200717A1 (es) Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
BR112023025904A2 (pt) Molécula de ligação biespecífica
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CO2018009533A2 (es) Conjugados de amanitina
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
AR076797A1 (es) Anticuerpos triespecificos o tetraespecificos
PE20141521A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
BR112015008311A2 (pt) conjugados fármaco-proteína
BR112023001005A2 (pt) Anticorpo anti-receptor de transferrina (tfr) e usos do mesmo
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
PE20120414A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
AR076193A1 (es) Anticuerpos biespecificos trivalentes
BR112021005722A2 (pt) moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente
AR064456A1 (es) Anticuerpos cd 44
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
CL2017000756A1 (es) Moléculas de unión, especialmente anticuerpos, que se unen a l1cam (cd171)
BR112016020492A2 (pt) fibronectina estabilizada com base nas estruturas de moléculas
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
BR112021020204A2 (pt) Método para purificar anticorpo com região fc modificada
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
BR112022026401A2 (pt) Conjugados anticorpo-fármaco compreendendo anticorpos anti-b7-h3